PMC9097224_01
(A) The abdominal computed tomography (CT) scan revealed a 5-cm mass at the pancreatic body with liver metastases at diagnosis. (B) After chemotherapy and RFA of liver metastasis, no [18F]-FDG uptake was identified at PET scan. (C) At 32 months after initial diagnosis, the patient remains disease-free under maintenance nivolumab alone.
fimmu-13-870406-g001.jpg
PMC9097224_01_fimmu-13-870406-g001.jpg
f1
An abdominal computed tomography (CT) scan ( Figure 1A ) revealed a 5-cm mass at the pancreatic body with liver metastases and the staging of cT4N1M1. April 2019, and reduced doses of the same chemotherapy agents were restarted concomitantly. After RFA, no [18F]-fluorodeoxyglucose uptake of liver tumors was identified through positron emission tomography ( Figure 1B ). At present, the patient is still receiving maintenance nivolumab alone every 6 weeks and remains disease-free ( Figure 1C ).
With extreme response to the SOLAR regimen, the level of CA 19-9 decreased rapidly. The lymphocyte count (LYM) decreased after chemotherapy and RT initially but recovered with maintenance nivolumab +- CIK cell therapy.
fimmu-13-870406-g002.jpg
PMC9097224_01_fimmu-13-870406-g002.jpg
f2
The treatment course is summarized in  Figure 2 .